Anbio Biotechnology Class A Ordinary Shares (NNNN) — Analysis Summary
Anbio Biotechnology Class A Ordinary Shares (NNNN) has a market cap of $341.47M with year-over-year revenue growth of +5.6%. Net margin stands at 74.1%. The stock trades at a P/E ratio of 53.3.
Key Takeaways
- Revenue changed +5.6% year-over-year
- Net margin of 74.1%
- P/E ratio of 53.3
Compared with its sector, NNNN posted revenue growth of +5.6% and trades at a P/E of 53.3.
Anbio Biotechnology Class A Ordinary Shares (NNNN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating cash flow is negative while net income remains positive.
Operating margin at 66.7% — exceptionally high, typical only for monopolistic or IP-heavy businesses
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Employees
27
Exchange
XNAS
At least 3 years of annual financial data required to assess competitive moat.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.